Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019033087) ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/033087 International Application No.: PCT/US2018/046398
Publication Date: 14.02.2019 International Filing Date: 11.08.2018
IPC:
C07K 16/18 (2006.01) ,C07K 16/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Applicants:
RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street Carson City, NV 89703, US
Inventors:
GEORGIOU, George; US
LEE, Chang-han; US
KANG, Tae, Hyun; US
Agent:
FINDLAY, Geoffrey, S.; US
Priority Data:
62/544,62211.08.2017US
Title (EN) ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE
(FR) VARIANTS D'ANTICORPS FC MODIFIÉS POUR DEMI-VIE SÉRIQUE AMÉLIORÉE
Abstract:
(EN) In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
(FR) Selon certains aspects, l'invention concerne des domaines Fc mutants ou variants présentant une liaison accrue à FcRn et une demi-vie accrue après administration in vivo. Le domaine Fc peut être incorporé dans un anticorps glycosylé ou aglycosylé. L'invention concerne également des procédés d'utilisation des domaines Fc mutants ou variants ou des polypeptides comprenant les domaines Fc mutants ou variants.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)